1. Home
  2. BBY vs INCY Comparison

BBY vs INCY Comparison

Compare BBY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBY
  • INCY
  • Stock Information
  • Founded
  • BBY 1966
  • INCY 1991
  • Country
  • BBY United States
  • INCY United States
  • Employees
  • BBY N/A
  • INCY N/A
  • Industry
  • BBY Consumer Electronics/Video Chains
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • BBY Consumer Discretionary
  • INCY Health Care
  • Exchange
  • BBY Nasdaq
  • INCY Nasdaq
  • Market Cap
  • BBY 16.0B
  • INCY 13.4B
  • IPO Year
  • BBY N/A
  • INCY 1993
  • Fundamental
  • Price
  • BBY $61.97
  • INCY $58.21
  • Analyst Decision
  • BBY Buy
  • INCY Hold
  • Analyst Count
  • BBY 19
  • INCY 20
  • Target Price
  • BBY $90.89
  • INCY $74.00
  • AVG Volume (30 Days)
  • BBY 5.5M
  • INCY 2.3M
  • Earning Date
  • BBY 05-29-2025
  • INCY 04-29-2025
  • Dividend Yield
  • BBY 6.13%
  • INCY N/A
  • EPS Growth
  • BBY N/A
  • INCY N/A
  • EPS
  • BBY 4.28
  • INCY 0.15
  • Revenue
  • BBY $41,528,000,000.00
  • INCY $4,241,216,999.00
  • Revenue This Year
  • BBY $0.84
  • INCY $12.21
  • Revenue Next Year
  • BBY $1.74
  • INCY $9.20
  • P/E Ratio
  • BBY $14.48
  • INCY $345.39
  • Revenue Growth
  • BBY N/A
  • INCY 14.76
  • 52 Week Low
  • BBY $54.99
  • INCY $50.35
  • 52 Week High
  • BBY $103.71
  • INCY $83.95
  • Technical
  • Relative Strength Index (RSI)
  • BBY 40.08
  • INCY 40.69
  • Support Level
  • BBY $59.16
  • INCY $57.05
  • Resistance Level
  • BBY $64.53
  • INCY $59.95
  • Average True Range (ATR)
  • BBY 4.35
  • INCY 2.76
  • MACD
  • BBY -0.01
  • INCY 0.18
  • Stochastic Oscillator
  • BBY 32.77
  • INCY 46.45

About BBY Best Buy Co. Inc.

With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: